Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorVanda Pharmaceuticals
About this trial
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Iloperidone for the Treatment of Participants with Uncontrolled Hypertension
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
SiSBP >/= 130 mmHg despite >8 weeks treatment w/ 1 or more antihypertensive therapies
Disqualifiers
Confirmed Grade 3/severe hypertension (SiSBP >/= 180 mmHg, SiDBP >/= 120 mmHg), unstable cardiac disease, renal insufficiency
Trial design
Design model
Parallel
Treatments tested in this trial
iloperidone
Drugiloperidone
Placebo
Drugplacebo comparator
Treatment groups
240 Participants
are divided into 2 treatment groupsGroup A: Experimental/IloperidoneExperimental treatment 1 intervention
Group B: Placebo ComparatorPlacebo comparator 1 intervention
Trial outcomes
Primary outcomes
1
Change from baseline to treatment week 4 in SiSBP
Time frame
screening to treatment week 4Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov